T. Rowe Price Associates, Inc. (funds/accounts advised)

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

2round participations

0lead positions

Mar 2022latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

SSandboxAQScienceSandboxAQ is an independent B2B company applying “Large Quantitative Models” (LQMs)—physics, chemistry, and…$5.3Bvaluation$2.1BraisedRecent roundsOther / 2024 round (company-described $300M+ funding) · Dec 2026$300M · Ava Investments, Breyer Capital +12Series F · Jun 2026Government award (CHIPS R&D award; non-dilutive stated by framing in release) · Jun 2026$500M · U.S. Department of Commerce (CHIPS Research and Development Office)SandboxAQ—Mar 2022 → Mar 20221 roundParticipant—

GTGenesis Therapeutics—Dec 2020 → Dec 20201 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Mar 22, 2022SSandboxAQScienceSandboxAQ is an independent B2B company applying “Large Quantitative Models” (LQMs)—physics, chemistry, and…$5.3Bvaluation$2.1BraisedRecent roundsOther / 2024 round (company-described $300M+ funding) · Dec 2026$300M · Ava Investments, Breyer Capital +12Series F · Jun 2026Government award (CHIPS R&D award; non-dilutive stated by framing in release) · Jun 2026$500M · U.S. Department of Commerce (CHIPS Research and Development Office)SandboxAQInitial/Launch funding (oversubscribed; terms/amount undisclosed)——Participant

Source ↗

Dec 02, 2020GTGenesis TherapeuticsSeries A$52M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Dec 02, 2020GTGenesis TherapeuticsSeries A$52M—Participant

Source ↗